<DOC>
	<DOCNO>NCT02291874</DOCNO>
	<brief_summary>Purpose study evaluate Long-term Safety , Tolerability , Efficacy Ipragliflozin Combination GLP-1 Receptor Agonists Japanese Patients Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control GLP-1 Receptor Agonists .</brief_summary>
	<brief_title>Post-Marketing Study Evaluate Long-term Safety , Tolerability , Efficacy Ipragliflozin Combination With GLP-1 Receptor Agonists Japanese Patients With Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description>This multicenter , open-label study patient T2DM inadequate glycemic control GLP-1 receptor agonist least 6 week prior Visit 1 ( Week −6 ) . Patients monotherapy Victoza® combination therapy GLP-1 receptor agonist sulfonylurea ( SU ) eligible . Patients combination therapy GLP-1 receptor agonists non-SU hypoglycemic agent also include ; however , patient must undergo washout non-SU hypoglycemic agent administer GLP-1 receptor agonist .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>The subject diagnosis T2DM determine least 12 week ( 84 day ) provide informed consent . The subject receive GLP1 receptor agonist fix dose mode administration least 6 week ( 42 day ) prior Visit 1 . If therapy concomitant SU , subject receive SU fix dose mode administration least 6 week ( 42 day ) prior Visit 1 . The subject HbA1c level ≥7.5 % ≤10.5 % Visit 2 , difference HbA1c level Visit 1 Visit 2 within ±1.0 % . The subject BMI ≥20.0 kg/m2 ≤45.0 kg/m2 Visit 2 . If therapy concomitant SU , subject fast plasma glucose level ≥126 mg/dL Visit 2 . The subject T1DM . The subject symptom dysuria , anuria , oliguria , urinary retention . The subject proliferative retinopathy . The subject history clinically significant renal disease renovascular occlusive disease , nephrectomy , renal transplant . The subject history pancreatitis . The subject history recurrent urinary tract infection ( ≥3 episode within 24 week provide informed consent ) . The subject symptomatic urinary tract infection symptomatic genital infection . The subject chronic disease require continuous use adrenocortical steroid immunosuppressant ( oral , injectable , inhalational medication ) . The subject history cerebral vascular attack , unstable angina , myocardial infarction , vascular intervention , serious heart disease ( NYHA Class IIIIV ) within 1 year ( 52 week ) prior Visit 1 , subject heart disease cerebral vascular disease , per judgment investigator subinvestigator , may interfere treatment ipragliflozin safety evaluation study . The subject unstable psychiatric disorder . The subject female currently pregnant lactating could pregnant . The subject unable unwilling practice appropriate contraception method study . The subject severe infection , perioperative serious trauma . The subject drug addiction abuse alcohol . The subject history malignant tumor ( except he/she free treatment least 5 year provide informed consent consider recurrence ) . The subject history allergy ipragliflozin similar drug SGLT2 inhibitory action . The subject participate clinical study investigational product medical device postmarketing study within 12 week ( 84 day ) provide informed consent currently participate study . The subject unable unwilling , agree , comply study requirement , include hospital visit , dose instruction , subject 's responsibility .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Ipragliflozin</keyword>
	<keyword>GLP-1 receptor agonist</keyword>
</DOC>